Figure 4.
The inhibitor of miR-486-5P partially reversed the protective role of BMSC-Exos on DEX -induced myotube atrophy. (A) The level of miR-486-5p in C2C12 myotube after treated with con or con+BMSC-Exos were measured by qRT-PCR analysis (n=3). *p < 0.05 compared to the control group. (B) The expression of miR-486-5P in C2C12 myotubes after treated with different exos was measured by qRT-PCR analysis (n = 3). *p < 0.05 compared to the con group, # p< 0.05 compared to the inhibitor NC Exos group, ## p< 0.05 compared to the mimics NC Exos group. (C, D) FoxO1 protein level in nuclear of C2C12 cells was measured and quantified (n=3). *p<0.05 compared to the con group, #p < 0.05 compared to the DEX group, &p < 0.05 compared to the DEX + inhibitor NC group, &&p < 0.05 compared to the DEX+mimics NC group. (E, F) Measurements of Atrogin-1, MuRF1, and MyoG protein in DEX and Exos co-treated C2C12 myotube (n = 3). *p < 0.05 compared to the con group, #p < 0.05 compared to the DEX group, &p < 0.05 compared to the DEX + inhibitor NC group, &&p < 0.05 compared to the DEX+mimics NC group.